196 related articles for article (PubMed ID: 32646514)
21. Oral and salivary gland angiosarcoma: a clinicopathologic study of 29 cases.
Fanburg-Smith JC; Furlong MA; Childers EL
Mod Pathol; 2003 Mar; 16(3):263-71. PubMed ID: 12640107
[TBL] [Abstract][Full Text] [Related]
22. Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease.
Momen S; Fassihi H; Davies HR; Nikolaou C; Degasperi A; Stefanato CM; Dias JML; Dasgupta D; Craythorne E; Sarkany R; Papa S; Nik-Zainal S
Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31645345
[TBL] [Abstract][Full Text] [Related]
23.
Xie HM; Bernt KM
Biomolecules; 2022 Aug; 12(8):. PubMed ID: 36009018
[TBL] [Abstract][Full Text] [Related]
24. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma.
Takai E; Omata W; Totoki Y; Nakamura H; Shiba S; Takahashi A; Namikawa K; Mori T; Yamazaki N; Shibata T; Yachida S
Cancer Sci; 2021 Nov; 112(11):4748-4757. PubMed ID: 34477284
[TBL] [Abstract][Full Text] [Related]
25. Case report: whole exome sequencing of primary cardiac angiosarcoma highlights potential for targeted therapies.
Zhrebker L; Cherni I; Gross LM; Hinshelwood MM; Reese M; Aldrich J; Guileyardo JM; Roberts WC; Craig D; Von Hoff DD; Mennel RG; Carpten JD
BMC Cancer; 2017 Jan; 17(1):17. PubMed ID: 28056866
[TBL] [Abstract][Full Text] [Related]
26. Biallelic
Hanna JA; Drummond CJ; Garcia MR; Go JC; Finkelstein D; Rehg JE; Hatley ME
Cancer Res; 2017 Nov; 77(22):6109-6118. PubMed ID: 28916654
[TBL] [Abstract][Full Text] [Related]
27. Angiosarcoma.
Young RJ; Brown NJ; Reed MW; Hughes D; Woll PJ
Lancet Oncol; 2010 Oct; 11(10):983-91. PubMed ID: 20537949
[TBL] [Abstract][Full Text] [Related]
28. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.
Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM
Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196
[TBL] [Abstract][Full Text] [Related]
29. Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE).
Swami N; Hwang WL; Guo JA; Hoffman H; Abramowitz MC; Elbakouny Z; Beltran H; Chipidza F; Choueiri T; Pra AD; Huang F; Kaochar S; Kantoff P; Kim DW; Kishan AU; Kobetz E; Marinac C; Mucci LA; Muralidhar V; Pollack A; Sanford NN; Schaeffer EM; Spratt DE; Zhao SG; Rebbeck TR; Nguyen PL; Feng FY; Mahal BA; Alshalalfa M
Cancer Genet; 2021 Nov; 258-259():61-68. PubMed ID: 34551377
[TBL] [Abstract][Full Text] [Related]
30. Recurrent PTPRB and PLCG1 mutations in angiosarcoma.
Behjati S; Tarpey PS; Sheldon H; Martincorena I; Van Loo P; Gundem G; Wedge DC; Ramakrishna M; Cooke SL; Pillay N; Vollan HKM; Papaemmanuil E; Koss H; Bunney TD; Hardy C; Joseph OR; Martin S; Mudie L; Butler A; Teague JW; Patil M; Steers G; Cao Y; Gumbs C; Ingram D; Lazar AJ; Little L; Mahadeshwar H; Protopopov A; Al Sannaa GA; Seth S; Song X; Tang J; Zhang J; Ravi V; Torres KE; Khatri B; Halai D; Roxanis I; Baumhoer D; Tirabosco R; Amary MF; Boshoff C; McDermott U; Katan M; Stratton MR; Futreal PA; Flanagan AM; Harris A; Campbell PJ
Nat Genet; 2014 Apr; 46(4):376-379. PubMed ID: 24633157
[TBL] [Abstract][Full Text] [Related]
31. PDK1 is a potential therapeutic target against angiosarcoma cells.
Wada M; Horinaka M; Yasuda S; Masuzawa M; Sakai T; Katoh N
J Dermatol Sci; 2015 Apr; 78(1):44-50. PubMed ID: 25726712
[TBL] [Abstract][Full Text] [Related]
32. Molecular determinants of response to PD-L1 blockade across tumor types.
Banchereau R; Leng N; Zill O; Sokol E; Liu G; Pavlick D; Maund S; Liu LF; Kadel E; Baldwin N; Jhunjhunwala S; Nickles D; Assaf ZJ; Bower D; Patil N; McCleland M; Shames D; Molinero L; Huseni M; Sanjabi S; Cummings C; Mellman I; Mariathasan S; Hegde P; Powles T
Nat Commun; 2021 Jun; 12(1):3969. PubMed ID: 34172722
[TBL] [Abstract][Full Text] [Related]
33. Next-generation sequencing for the management of sarcomas with no known driver mutations.
Vyse S; Thway K; Huang PH; Jones RL
Curr Opin Oncol; 2021 Jul; 33(4):315-322. PubMed ID: 33927108
[TBL] [Abstract][Full Text] [Related]
34. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer.
Anagnostou V; Niknafs N; Marrone K; Bruhm DC; White JR; Naidoo J; Hummelink K; Monkhorst K; Lalezari F; Lanis M; Rosner S; Reuss JE; Smith KN; Adleff V; Rodgers K; Belcaid Z; Rhymee L; Levy B; Feliciano J; Hann CL; Ettinger DS; Georgiades C; Verde F; Illei P; Li QK; Baras AS; Gabrielson E; Brock MV; Karchin R; Pardoll DM; Baylin SB; Brahmer JR; Scharpf RB; Forde PM; Velculescu VE
Nat Cancer; 2020 Jan; 1(1):99-111. PubMed ID: 32984843
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment.
Arrieta VA; Dmello C; McGrail DJ; Brat DJ; Lee-Chang C; Heimberger AB; Chand D; Stupp R; Sonabend AM
J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36647828
[TBL] [Abstract][Full Text] [Related]
36. Mutational landscape of primary breast angiosarcoma with repeated resection and recurrence over a 15-year period: A case report.
Teruyama F; Kuno A; Murata Y; Nakagawa T; Shiba-Ishii A; Yuguchi S; Noguchi M
Pathol Int; 2022 Sep; 72(9):457-463. PubMed ID: 35801418
[TBL] [Abstract][Full Text] [Related]
37. Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.
Hong TH; Cha H; Shim JH; Lee B; Chung J; Lee C; Kim NKD; Choi YL; Hwang S; Lee Y; Park S; Jung HA; Kim JY; Park YH; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH; Park WY
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33077514
[TBL] [Abstract][Full Text] [Related]
38. Application of Immune Checkpoint Inhibitors in the Treatment of Cholangiocarcinoma.
Zeng FL; Chen JF
Technol Cancer Res Treat; 2021; 20():15330338211039952. PubMed ID: 34528830
[TBL] [Abstract][Full Text] [Related]
39. New risk factors and molecular landscapes of hepatic angiosarcoma in the Taiwanese population
Chung F; Zavadil J
J Pathol; 2024 Jan; 262(1):1-3. PubMed ID: 37929656
[TBL] [Abstract][Full Text] [Related]
40. Spontaneous regression of chemotherapy-resistant metastases from a scalp angiosarcoma.
Suzuki M; Matsuzuka T; Ikeda M; Nakaegawa Y; Kobayashi T; Kawase T; Kobari T; Murono S
Fukushima J Med Sci; 2017 Aug; 63(2):106-111. PubMed ID: 28680008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
